Skip Navigation



Carcinogenesis Advance Access published online on April 8, 2004
Carcinogenesis, doi:10.1093/carcin/bgh162
© 2004 by Oxford University Press
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
25/9/1721    most recent
bgh162v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Munday, R.
Right arrow Articles by Munday, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munday, R.
Right arrow Articles by Munday, C. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION

Induction of Phase II enzymes by 3H-1,2-dithiole-3-thione: dose-response study in rats

Rex Munday 1* and Christine M. Munday 1

1 AgResearch, Ruakura Agricultural Research Centre, Private Bag 3123, Hamilton, New Zealand

* Corresponding author. E-mail: rex.munday{at}agresearch.co.nz.

Received 2 March 2004 ; accepted 31 March 2004

Abstract

Derivatives of 3H-1,2-dithiole-3-thione (D3T) are known to protect against a variety of chemical carcinogens. There is evidence that this chemoprotective effect depends, at least in part, on the ability of these compounds to increase tissue activities of Phase II detoxification enzymes. In the present study, D3T was dosed to rats at daily doses of between 0.98 and 125 µmoles/kg/day for 5 days. The activity of two Phase II enzymes, quinone reductase and glutathione-S-transferase, were then assayed in the liver, spleen, kidneys, lungs, heart, urinary bladder, forestomach, glandular stomach, duodenum, jejunum, ileum, caecum and colon plus rectum of the animals. D3T was particularly effective in increasing enzyme activities in the stomach and duodenum, with significant effects being recorded at a dose-level of only 0.98 µmoles/kg/day. At slightly higher dose-levels, increases were recorded in other segments of the small and large intestine and in the urinary bladder. D3T caused enlargement of the liver, kidneys, stomach and intestinal tract of the animals at the higher dose-levels, but no other toxic effects were recorded. D3T is a very effective inducer of Phase II enzymes, showing significant effects at lower dose-levels than any other compound for which dose-response data are available. The inductive potency of D3T makes it a most promising candidate for use as a chemoprotective agent.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
Y. Zhang and R. Munday
Dithiolethiones for cancer chemoprevention: where do we stand?
Mol. Cancer Ther., November 1, 2008; 7(11): 3470 - 3479.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.